

Docket No. 249.0002 0101

**DECLARATION**

I, Dominic E. COSGROVE, the sole inventor of the invention claimed, declare that: (1) my citizenship and residence/mailing address are indicated below; (2) I have reviewed and understand the contents of the specification identified below, including the claims, as appended by any amendment specifically referred to herein. (3) I believe that I am the original and first inventor of the subject matter in

**IMMUNODIAGNOSTIC DETERMINATION OF USHER SYNDROME TYPE IIA**

Filed: Herewith

Serial No.: Unassigned

described and claimed therin and for which a patent is sought; and (4) I hereby acknowledge my duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to the patentability as defined in Title 37, Code of Federal Regulations, §1.56.\*

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate listed below, or §365(a) of any PCT international application which designates at least one country other than the United States of America listed below, and have also identified below any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on the basis of which priority is claimed

a.  no such applications have been filed.  
b.  such applications have been filed as follows:

**FOREIGN APPLICATION(S), IF ANY, CLAIMING PRIORITY UNDER  
35 USC §119(a)-(d), §365(a), and/or §365(b)**

COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)
NONE			

**ALL FOREIGN APPLICATIONS, IF ANY, FILED BEFORE THE PRIORITY APPLICATION(S)**

COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)
NONE			

\*Title 37, Code of Federal Regulations, §1.56 is reproduced on the attached page.

2025 RELEASE UNDER E.O. 14176

**Declaration**

Serial No : Unassigned  
 Confirm. No. Unassigned  
 Filing Date: Herewith (03 October 2001)  
 Title: IMMUNODIAGNOSTIC DETERMINATION OF USHER SYNDROME TYPE IIA

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

a.        no such applications have been filed.  
 b. X such applications have been filed as follows:

<b>PROVISIONAL APPLICATION(S), IF ANY, UNDER 35 USC §119(e)</b>	
<b>APPLICATION NUMBER</b>	<b>DATE OF FILING (day, month, year)</b>
<u>60/237,834</u>	<u>03 October 2000</u>

I hereby claim the benefit under Title 35, United States Code, §120 of any United States applications or §365(c) of any PCT international application(s) designating the United States of America listed below.


a. X no such applications have been filed  
 b.        such applications have been filed as follows:


<b>APPLICATION NUMBER</b>	<b>DATE OF FILING (day, month, year)</b>	<b>STATUS (patented, pending, abandoned)</b>
<u>NONE</u>		

Insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

The undersigned declares further that all statements made herein of his/her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Wherefore, I pray that Letters Patent be granted to me for the invention described and claimed in the specification identified above and I hereby subscribe my name to the foregoing specification, claims, and Declaration on the date indicated below.

  
 Dominic E. COSGROVE  
 Citizenship: US  
 Residence: 5612 Howard Street, Omaha, Nebraska 68106 (US)  
 Mailing Address: Same  
 (If different than Residence)

  
 Date

**Declaration**

Serial No.: Unassigned  
Confirm. No.: Unassigned  
Filing Date: Herewith (03 October 2001)  
Title: JMMUNODIAGNOSTIC DETERMINATION OF USHER SYNDROME TYPE IIA

**§ 1.56 Duty to disclose information material to patentability.**

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

- (1) Prior art cited in search reports of a foreign patent office in a counterpart application, and
- (2) The closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

(b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

- (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim, or
- (2) It refutes, or is inconsistent with, a position the applicant takes in:
  - (i) Opposing an argument of unpatentability relied on by the Office, or
  - (ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

(c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:

- (1) Each inventor named in the application;
- (2) Each attorney or agent who prepares or prosecutes the application; and
- (3) Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.

(d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor

(e) In any continuation-in part application, the duty under this section includes the duty to disclose to the Office all information known to the person to be material to patentability, as defined in paragraph (b) of this section, which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in part application.

PATENT  
Docket No. 249.0002 0101

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Dominic E. COSGROVE	)	Group Art Unit:	Unassigned
		)		
Serial No.:	Unassigned	)	Examiner:	Unassigned
Confirmation No.:	Unassigned	)		
Filed:	Herewith (03 October 2001)	)		
For:	IMMUNODIAGNOSTIC DETERMINATION OF USHER SYNDROME TYPE II A			

---

ELECTION UNDER 37 C.F.R. §3.71, REVOCATION,  
POWER OF ATTORNEY, AND CERTIFICATE UNDER §3.73(b)

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

The Assignee BOYSTOWN NATIONAL RESEARCH HOSPITAL of the  
entire interest in the above-identified application hereby elects, under 37 C.F.R. §3.71, to  
prosecute the application to the exclusion of the inventor.

The Assignee hereby revokes any previous Powers of Attorney and appoints:

Adams, Matthew W.	Reg. No. 43,459
Albin, Loren D.	Reg. No. 37,763
Franklin, Kathleen L.	Reg. No. 47,574
Gebhardt, Mark J.	Reg. No. 35,518
Huebsch, Joseph C.	Reg. No. 42,673
Muetting, Ann M.	Reg. No. 33,977
Provence, David L.	Reg. No. 43,022
Raasch, Kevin W.	Reg. No. 35,651
Sandberg, Victoria A.	Reg. No. 41,287
Walsh, Brian J.	Reg. No. 45,543

as its attorney or agent (with full powers of appointment, substitution and revocation) to  
prosecute the application, and any division, continuation, continuation-in-part, reexamination or  
reissue thereof, to make alterations and amendments therein, and to transact all business in the  
Patent and Trademark Office in connection therewith, and to receive any Letters Patent.

Election Under 37 C.F.R. §§3.71, Revocation, Power of Attorney and Certificate under §3.73(b) Page 2 of 2  
Serial No.: Unassigned  
Confirm. No.: Unassigned  
Filed: Herewith (03 October 2001)  
Title: IMMUNODIAGNOSTIC DETERMINATION OF USHER SYNDROME TYPE IIA

Please send correspondence to the following address:

Attention: Ann M. Mueting  
Mueting, Raasch & Gebhardt, P.A.  
P.O. Box 581415  
Minneapolis, MN 55458-1415  
Customer Number 26,813

BOYSTOWN NATIONAL RESEARCH HOSPITAL, a corporation organized and existing under and by virtue of the laws of the State of Nebraska, and having an office and place of business at 555 North 30<sup>th</sup> Street, Omaha, Nebraska 68131 (US), certifies that it is the assignee of the entire right, title, and interest in the patent application identified above by virtue of an assignment from the inventors, a copy of which is attached. I have reviewed all the documents in the chain of title of the patent application identified above and, to the best of my knowledge and belief, title is in the assignee identified above.

I am empowered to sign this certificate on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

ASSIGNEE:

BOYSTOWN NATIONAL RESEARCH  
HOSPITAL

October 3, 2001  
Date

Walt Jesterdt  
Signature

WALT JESTERDT  
Typed or Printed Name

DIRECTOR OF RESEARCH  
Title